Abstract Session 6

Co-Chair(s)

• 

  Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his)

  Professor of Medicine, Director of Myeloma Research
  NYU Langone Health Perlmutter Cancer Center
  New York, New York
• LQ

  Lugui Qiu, MD (he/him/his)

  Department Head
  Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  Tianjin , China (People's Republic)

Presentations:

• 16:00 - 16:10 East Coast USA Time

  (OA-01) TET2 and EZH2 Genetic Alterations Promote Malignant CAR-T Transformation in Anti-BCMA CAR-T Therapy
  

  Abstract Presenter: Adolfo Aleman, PhD – Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
• 16:10 - 16:20 East Coast USA Time

  (OA-09) A Syngeneic Mouse Model of CAR-T Cell Therapy Containing a Translatable Dual Human/Mouse Reactive sdAb Binder in Vk*MYC Mice Reveals Clinically-Relevant Microenvironment Changes
  

  Abstract Presenter: Lorenzo Lindo, BSc (he/him/his) – Basic and Translational Department, BC Cancer Research Institute
• 16:20 - 16:30 East Coast USA Time

  (OA-06) Inactivation of TRAF3 and CYLD Drive Resistance to T-Cell Based Therapies in Multiple Myeloma by Promoting Inflammation and an Immunosuppressive Microenvironment that Impair T Cell Function
  

  Abstract Presenter: David Jung, BSc (he/him/his) – University of Calgary
• 16:30 - 16:40 East Coast USA Time

  (OA-04) CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy
  

  Abstract Presenter: Matthew Ho, MD, PhD – University of Pennsylvania
• 16:40 - 16:50 East Coast USA Time

  (OA-32) Idecabtagene Vicleucel (ide-cel) and Endogenous Immune Profiles Linked to Progression-Free Survival in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
  

  Abstract Presenter: Bruno Paiva, PhD – Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain